MultiPlan Competitors

MultiPlan (NYSE:MPLN) and Fair Isaac (NYSE:FICO) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, risk and institutional ownership.

Analyst Ratings

This is a summary of recent recommendations for MultiPlan and Fair Isaac, as provided by MarketBeat.com.

MultiPlan presently has a consensus target price of $9.25, suggesting a potential upside of 48.00%. Fair Isaac has a consensus target price of $536.00, suggesting a potential upside of 3.41%. Given MultiPlan's higher probable upside, equities research analysts plainly believe MultiPlan is more favorable than Fair Isaac.

Valuation & Earnings

This table compares MultiPlan and Fair Isaac's top-line revenue, earnings per share (EPS) and valuation.

Fair Isaac has higher revenue and earnings than MultiPlan.

Profitability

This table compares MultiPlan and Fair Isaac's net margins, return on equity and return on assets.

Institutional and Insider Ownership

0.1% of MultiPlan shares are held by institutional investors. Comparatively, 84.9% of Fair Isaac shares are held by institutional investors. 3.8% of Fair Isaac shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Fair Isaac beats MultiPlan on 8 of the 9 factors compared between the two stocks.

MultiPlan (NYSE:MPLN) and The Western Union (NYSE:WU) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, risk and institutional ownership.

Analyst Ratings

This is a summary of recent recommendations for MultiPlan and The Western Union, as provided by MarketBeat.com.

MultiPlan presently has a consensus target price of $9.25, suggesting a potential upside of 48.00%. The Western Union has a consensus target price of $23.7667, suggesting a potential downside of 5.65%. Given MultiPlan's stronger consensus rating and higher probable upside, equities research analysts plainly believe MultiPlan is more favorable than The Western Union.

Valuation & Earnings

This table compares MultiPlan and The Western Union's top-line revenue, earnings per share (EPS) and valuation.

The Western Union has higher revenue and earnings than MultiPlan.

Profitability

This table compares MultiPlan and The Western Union's net margins, return on equity and return on assets.

Institutional and Insider Ownership

0.1% of MultiPlan shares are held by institutional investors. 1.3% of The Western Union shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

The Western Union beats MultiPlan on 5 of the 9 factors compared between the two stocks.

MultiPlan (NYSE:MPLN) and WEX (NYSE:WEX) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, risk and institutional ownership.

Analyst Ratings

This is a summary of recent recommendations for MultiPlan and WEX, as provided by MarketBeat.com.

MultiPlan presently has a consensus target price of $9.25, suggesting a potential upside of 48.00%. WEX has a consensus target price of $199.7143, suggesting a potential downside of 8.94%. Given MultiPlan's stronger consensus rating and higher probable upside, equities research analysts plainly believe MultiPlan is more favorable than WEX.

Valuation & Earnings

This table compares MultiPlan and WEX's top-line revenue, earnings per share (EPS) and valuation.

WEX has higher revenue and earnings than MultiPlan.

Profitability

This table compares MultiPlan and WEX's net margins, return on equity and return on assets.

Institutional and Insider Ownership

0.1% of MultiPlan shares are held by institutional investors. Comparatively, 98.7% of WEX shares are held by institutional investors. 0.8% of WEX shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

WEX beats MultiPlan on 7 of the 9 factors compared between the two stocks.

MultiPlan (NYSE:MPLN) and Nielsen (NYSE:NLSN) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, risk and institutional ownership.

Analyst Ratings

This is a summary of recent recommendations for MultiPlan and Nielsen, as provided by MarketBeat.com.

MultiPlan presently has a consensus target price of $9.25, suggesting a potential upside of 48.00%. Nielsen has a consensus target price of $24.00, suggesting a potential downside of 6.14%. Given MultiPlan's stronger consensus rating and higher probable upside, equities research analysts plainly believe MultiPlan is more favorable than Nielsen.

Valuation & Earnings

This table compares MultiPlan and Nielsen's top-line revenue, earnings per share (EPS) and valuation.

MultiPlan has higher earnings, but lower revenue than Nielsen.

Profitability

This table compares MultiPlan and Nielsen's net margins, return on equity and return on assets.

Institutional and Insider Ownership

0.1% of MultiPlan shares are held by institutional investors. 0.4% of Nielsen shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Nielsen beats MultiPlan on 5 of the 9 factors compared between the two stocks.

MultiPlan (NYSE:MPLN) and Shift4 Payments (NYSE:FOUR) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, risk and institutional ownership.

Analyst Ratings

This is a summary of recent recommendations for MultiPlan and Shift4 Payments, as provided by MarketBeat.com.

MultiPlan presently has a consensus target price of $9.25, suggesting a potential upside of 48.00%. Shift4 Payments has a consensus target price of $66.00, suggesting a potential downside of 34.91%. Given MultiPlan's stronger consensus rating and higher probable upside, equities research analysts plainly believe MultiPlan is more favorable than Shift4 Payments.

Valuation & Earnings

This table compares MultiPlan and Shift4 Payments' top-line revenue, earnings per share (EPS) and valuation.

Profitability

This table compares MultiPlan and Shift4 Payments' net margins, return on equity and return on assets.

Institutional and Insider Ownership

0.1% of MultiPlan shares are held by institutional investors. Comparatively, 33.4% of Shift4 Payments shares are held by institutional investors. 12.2% of Shift4 Payments shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Shift4 Payments beats MultiPlan on 3 of the 5 factors compared between the two stocks.

MultiPlan (NYSE:MPLN) and Concentrix (NASDAQ:CNXC) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, risk and institutional ownership.

Analyst Ratings

This is a summary of recent recommendations for MultiPlan and Concentrix, as provided by MarketBeat.com.

MultiPlan presently has a consensus target price of $9.25, suggesting a potential upside of 48.00%. Concentrix has a consensus target price of $122.50, suggesting a potential downside of 20.45%. Given MultiPlan's higher probable upside, equities research analysts plainly believe MultiPlan is more favorable than Concentrix.

Valuation & Earnings

This table compares MultiPlan and Concentrix's top-line revenue, earnings per share (EPS) and valuation.

Concentrix has higher revenue and earnings than MultiPlan.

Profitability

This table compares MultiPlan and Concentrix's net margins, return on equity and return on assets.

Institutional and Insider Ownership

0.1% of MultiPlan shares are held by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.